Elizabeth. F. Bode
Research Subjects
Elizabeth. F. Bode has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Andrew William Trafford
Manchester University
5 shared publications - David A. Eisner
University of Manchester
4 shared publications - Elzbieta Mederska
Univ Liverpool, Small Anim Teaching Hosp, Sch Vet Sci, Leahurst Campus Chester High Rd, Neston CH64 7TE, England
3 shared publications - David A. Singleton
IVC Evidensia UK, The Chocolate Factory, Keynsham, Bristol, BS31 2AU UK
2 shared publications G.J. Culshaw
Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Roslin EH25 9RG, UK; University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, EH16 4TJ, UK
2 shared publications- Joannna Dukes McEwan
Small Animal Teaching Hospital, Department of Small Animal Clinical Science, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst Campus, Chester High Road, Neston CH64 7TE UK
2 shared publications
Latest Publications
- 12 March 2025
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 59, 43-47
Idiopathic spontaneous intracardiac microbubbles in an adult dog
- 12 March 2025
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 59, 43-47
Idiopathic spontaneous intracardiac microbubbles in an adult dog
- Open Access
- 12 September 2023
- Published by Springer Nature in Research Square
Assessment of blood microRNA expression patterns by predictive classification algorithms can diagnose myxomatous mitral valve disease in dogs
Background: Myxomatous Mitral Valve Disease (MMVD) is a commonly presenting and progressive cardiac pathology in dogs, and early medical intervention can delay progression. Current cardiac biomarkers can be useful in advanced clinical MMVD cases, but are unreliable in pre-clinical disease.Objectives:Assessment of canine serum and plasma expression profiles of 15 miRNA markers as a method to accurately discriminate MMVD patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical (stage B1/B2) from clinical (stage C/D) MMVD patients.Animals:Client-owned dogs (n = 123) were recruited. Following sample exclusions (n=26), healthy controls (n=50) and MMVD cases (n=47) were analyzedMethods:Multicenter, cross-sectional, retrospective investigation. MicroRNA expression profiles were compared between dogs, and the performance of predictive modelling to distinguish healthy controls from MMVD patients, and pre-clinical from clinical MMVD patients was evaluated.Results:Analysis of miRNA expression patterns by predictive classification algorithms could differentiate healthy controls from dogs with MMVD (sensitivity 0.85; specificity 0.82; accuracy; 0.83). Discrimination of pre-clinical (n=29) from clinical (n=18) MMVD cases resulted in promising results (sensitivity 0.61; specificity 0.79; accuracy 0.73). The method also compared advantageously to current biomarkers in a limited population.Conclusions and clinical importance:The analysis of miRNA expression profiles by probabilistic predictive classification algorithms provides a useful diagnostic tool to distinguish healthy controls from MMVD cases (stage B1 to D). Discrimination between pre-clinical and clinical MMVD cases by the same method yielded promising results, which could be further enhanced with an increased study population.
- 12 September 2023
- Published by Springer Nature in Research Square
Open AccessAssessment of blood microRNA expression patterns by predictive classification algorithms can diagnose myxomatous mitral valve disease in dogs
Background: Myxomatous Mitral Valve Disease (MMVD) is a commonly presenting and progressive cardiac pathology in dogs, and early medical intervention can delay progression. Current cardiac biomarkers can be useful in advanced clinical MMVD cases, but are unreliable in pre-clinical disease.Objectives:Assessment of canine serum and plasma expression profiles of 15 miRNA markers as a method to accurately discriminate MMVD patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical (stage B1/B2) from clinical (stage C/D) MMVD patients.Animals:Client-owned dogs (n = 123) were recruited. Following sample exclusions (n=26), healthy controls (n=50) and MMVD cases (n=47) were analyzedMethods:Multicenter, cross-sectional, retrospective investigation. MicroRNA expression profiles were compared between dogs, and the performance of predictive modelling to distinguish healthy controls from MMVD patients, and pre-clinical from clinical MMVD patients was evaluated.Results:Analysis of miRNA expression patterns by predictive classification algorithms could differentiate healthy controls from dogs with MMVD (sensitivity 0.85; specificity 0.82; accuracy; 0.83). Discrimination of pre-clinical (n=29) from clinical (n=18) MMVD cases resulted in promising results (sensitivity 0.61; specificity 0.79; accuracy 0.73). The method also compared advantageously to current biomarkers in a limited population.Conclusions and clinical importance:The analysis of miRNA expression profiles by probabilistic predictive classification algorithms provides a useful diagnostic tool to distinguish healthy controls from MMVD cases (stage B1 to D). Discrimination between pre-clinical and clinical MMVD cases by the same method yielded promising results, which could be further enhanced with an increased study population.
- 28 June 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 49, 9-28
Pacemaker-lead-associated thrombosis in dogs: a multicenter retrospective study
- 28 June 2023
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 49, 9-28
Pacemaker-lead-associated thrombosis in dogs: a multicenter retrospective study
- 1 June 2021
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 35, 63-73
Clinical and diagnostic imaging findings in dogs with atrial appendage aneurysm: 7 cases (2014–2020)
- 1 June 2021
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 35, 63-73
Clinical and diagnostic imaging findings in dogs with atrial appendage aneurysm: 7 cases (2014–2020)
- 2 April 2021
- Published by Mark Allen Group in Companion Animal
- Vol. 26 (4) , 1-9
Pulmonary hypertension in dogs: an overview
Pulmonary hypertension is a complex syndrome that can be caused by congenital or acquired disease. Congenital conditions include cardiac shunts, such as ventricular septal defect and patent ductus arteriosus. Acquired diseases that eventually lead to pulmonary hypertension include cardiac, systemic and pulmonary pathologies, for example late stage myxomatous mitral valve disease and interstitial lung disease such as idiopathic pulmonary fibrosis. It can be a challenge to identify pulmonary hypertension because the diagnostic process usually requires advanced imaging tools, such as echocardiography, and a good understanding of the animal's history. Pulmonary hypertension can have a profound effect on a dog's quality of life and can lead to severe respiratory distress and damage to the cardiovascular system. Therefore pulmonary hypertension needs to be identified and addressed promptly. Pulmonary hypertension can be reversible in the early stages, but it is generally not reversible when chronic changes to the pulmonary vasculature have occurred. The article reviews the definition of pulmonary hypertension and its pathophysiology, its diagnosis and treatment in canine patients, and discusses the most common congenital and acquired causes.
- 2 April 2021
- Published by Mark Allen Group in Companion Animal
- Vol. 26 (4) , 1-9
Pulmonary hypertension in dogs: an overview
Pulmonary hypertension is a complex syndrome that can be caused by congenital or acquired disease. Congenital conditions include cardiac shunts, such as ventricular septal defect and patent ductus arteriosus. Acquired diseases that eventually lead to pulmonary hypertension include cardiac, systemic and pulmonary pathologies, for example late stage myxomatous mitral valve disease and interstitial lung disease such as idiopathic pulmonary fibrosis. It can be a challenge to identify pulmonary hypertension because the diagnostic process usually requires advanced imaging tools, such as echocardiography, and a good understanding of the animal's history. Pulmonary hypertension can have a profound effect on a dog's quality of life and can lead to severe respiratory distress and damage to the cardiovascular system. Therefore pulmonary hypertension needs to be identified and addressed promptly. Pulmonary hypertension can be reversible in the early stages, but it is generally not reversible when chronic changes to the pulmonary vasculature have occurred. The article reviews the definition of pulmonary hypertension and its pathophysiology, its diagnosis and treatment in canine patients, and discusses the most common congenital and acquired causes.
- 1 April 2020
- Published by Elsevier in The Veterinary Journal
- Vol. 258, 105456
Glucocorticoid metabolism and the action of 11 beta-hydroxysteroid dehydrogenase 2 in canine congestive heart failure
- 1 April 2020
- Published by Elsevier in The Veterinary Journal
- Vol. 258, 105456
Glucocorticoid metabolism and the action of 11 beta-hydroxysteroid dehydrogenase 2 in canine congestive heart failure
- 1 February 2019
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 21, 10-17
Total anomalous pulmonary venous connection in a mature dog
- 1 February 2019
- Published by Elsevier in Journal of Veterinary Cardiology
- Vol. 21, 10-17
Total anomalous pulmonary venous connection in a mature dog
- Open Access
- 26 December 2015
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 71 (12) , 1544-1552
Temporal Development of Autonomic Dysfunction in Heart Failure: Effects of Age in an Ovine Rapid-pacing Model
Heart failure (HF) is predominantly a disease of older adults and characterized by extensive sympatho-vagal imbalance leading to impaired reflex control of heart rate (HR). However, whether aging influences the development or extent of the autonomic imbalance in HF remains unclear. To address this, we used an ovine model of aging with tachypacing-induced HF to determine whether aging affects the chronotropic and inotropic responses to autonomic stimulation and reduction in heart rate variability (HRV) in HF. We find that aging is associated with increased cardiac dimensions and reduced contractility before the onset of tachypacing, and these differences persist in HF. Additionally, the chronotropic response to β-adrenergic stimulation was markedly attenuated in HF, and this occurred more rapidly in aged animals. By measuring HR during sequential autonomic blockade, our data are consistent with a reduced parasympathetic control of resting HR in aging, with young HF animals having an attenuated sympathetic influence on HR. Time-domain analyses of HR show a reduction in HRV in both young and aged failing animals, although HRV is lowest in aged HF. In conclusion, aging is associated with altered autonomic control and β-adrenergic responsiveness of HR, and these are exacerbated with the development of HF.
- 26 December 2015
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 71 (12) , 1544-1552
Open AccessTemporal Development of Autonomic Dysfunction in Heart Failure: Effects of Age in an Ovine Rapid-pacing Model
Heart failure (HF) is predominantly a disease of older adults and characterized by extensive sympatho-vagal imbalance leading to impaired reflex control of heart rate (HR). However, whether aging influences the development or extent of the autonomic imbalance in HF remains unclear. To address this, we used an ovine model of aging with tachypacing-induced HF to determine whether aging affects the chronotropic and inotropic responses to autonomic stimulation and reduction in heart rate variability (HRV) in HF. We find that aging is associated with increased cardiac dimensions and reduced contractility before the onset of tachypacing, and these differences persist in HF. Additionally, the chronotropic response to β-adrenergic stimulation was markedly attenuated in HF, and this occurred more rapidly in aged animals. By measuring HR during sequential autonomic blockade, our data are consistent with a reduced parasympathetic control of resting HR in aging, with young HF animals having an attenuated sympathetic influence on HR. Time-domain analyses of HR show a reduction in HRV in both young and aged failing animals, although HRV is lowest in aged HF. In conclusion, aging is associated with altered autonomic control and β-adrenergic responsiveness of HR, and these are exacerbated with the development of HF.